



Contact:
Michael LaFleur

Location:
Boston, MA

Email:
info@arietiscorp.com

Tel:
617.286.2165

Website:
<http://www.arietis.org>



Company Profile

Industry Sector: Healthcare, Pharmaceuticals


Company Overview: Arietis Pharma is a private, pharmaceutical company developing new antibiotics to cure resistant and complicated bacterial infections.

Target Market(s): Major Hospitals and outpatient clinics



Key Value Drivers

traditional inhibitor antibiotic




The Present

DISADVANTAGES:

- Incomplete killing
- Recurrence
- Resistance
- Limited biofilm activity

"active" ADEP antibiotic



The Proposed Future

ADVANTAGES:

- Rapid killing
- Complete killing
- Prevents recurrence
- Novel mechanism

EFFECTIVE AGAINST:

- Biofilms
- Dormant cells
- Resistant strains



Management

Leadership:

Dr. Kim Lewis is the founder and chairman of the board of Arietis, and a professor of biology at Northeastern University.

Dr. Michael LaFleur (COO) leads R&D at Arietis. He initiated the collaboration with Dr. Lee to optimize ClpP activating antibiotics, and obtained the exclusive license for their development.

Dr. Ken Coleman is the CSO who has more than 35 years of experience in antimicrobial drug discovery and development in both large pharma and small biotech companies.

Richard Lee, PhD, is a specialist in the medicinal chemistry of anti-infectives who optimized the ADEPs.



Technology

Technology: Arietis is developing optimized ADEP antibiotics to cure drug resistant infections such as methicillin resistant *Staphylococcus aureus* and vancomycin resistant enterococci.

Competitive Advantage: ADEP antibiotics activate the ClpP protease. Cells cannot escape death by shutting down or waiting until levels drop like for inhibitory antibiotics. ADEPs will allow common infections to be treated more quickly and effectively with less recurrence, while prosthetic joint infections may be cured with antibiotics for the first time.

Plan & Strategy: Arietis will build portfolio value by advancing the ClpP activator program through in vivo proof of concept and GLP safety studies. Then, we will license the technology to pharma partners who will ultimately bring the innovation to market.